CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

NCT05215470 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Renal Cancer Metastatic

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Hospital das Clínicas de Ribeirão Preto

Collaborators

[object Object]
[object Object]